Non-Fiction Books:

Reducing Race Differences in Direct-to-Consumer Pharmaceutical Advertising

Sorry, this product is not currently available to order

Here are some other products you might consider...

Reducing Race Differences in Direct-to-Consumer Pharmaceutical Advertising

The Case for Regulation

Customer rating

Click to share your rating 0 ratings (0.0/5.0 average) Thanks for your vote!

Share this product

Reducing Race Differences in Direct-to-Consumer Pharmaceutical Advertising by Stephany De Scisciolo
Sorry, this product is not currently available to order


Reducing health disparities by increasing access to health information is a national health policy priority. Evidence exists that direct-to-consumer pharmaceutical advertising (DTCA) is effective in educating consumers about health issues. However, racial disparities exist in such advertising. In 2009, the Food and Drug Administration (FDA) issued a report that included recommendations for enhancing the ability of DTCA to reach disadvantaged populations, including racial and ethnic minorities. Reducing Race Differences in Direct to Consumer Pharmaceutical Advertising compares the pharmaceutical advertisements placed in five popular women's magazines published prior to and following the 2009 FDA report to assess the impact of these recommendations on the content and appearance of advertisements placed in magazines of differing racial orientation. From a health policy perspective, the results are disappointing. The FDA recommendations had no impact on the frequency or content of the DTCA appearing in White-oriented versus Black-oriented magazines. In fact, far fewer drugs used to treat life-threatening conditions were advertised in Black-oriented magazines after the 2009 FDA recommendations. The book concludes that enhancing the educational and motivational value of DTCA will require more than a set of recommendations. The results shed light on the pharmaceutical industry's compliance with both hard and soft regulation. Neither federal recommendations nor industry guidelines resulted in the changes to DTCA envisioned by the FDA. Regulatory action is necessary to ensure that pharmaceutical companies develop advertising campaigns that not only promote their products, but also positively impact the health outcomes of those who read their ads.

Author Biography

Stephany De Scisciolo is senior executive with a national nonprofit dedicated to improving the health and well-being of disadvantaged communities and those that live within them. Teresa L. Scheid is professor of sociology at the University of North Carolina at Charlotte.
Release date NZ
August 31st, 2018
Country of Publication
United States
4 Graphs; 15 Tables, unspecified; 4 Halftones, black and white
Lexington Books
Product ID

Customer reviews

Nobody has reviewed this product yet. You could be the first!

Write a Review

Marketplace listings

There are no Marketplace listings available for this product currently.
Already own it? Create a free listing and pay just 9% commission when it sells!

Sell Yours Here

Help & options

  • If you think we've made a mistake or omitted details, please send us your feedback. Send Feedback
  • If you have a question or problem with this product, visit our Help section. Get Help
Filed under...

Buy this and earn 729 Banana Points